Tenaya Therapeutics reported Q1 2026 results just after Wednesday's close. The headline number landed on both sides of the ledger — EPS of -$0.09 missed the -$0.06 estimate, but revenue of $25 million crushed the $10 million Street consensus by a factor of two and a half. That split outcome is the defining tension for the stock heading into the next session.
Short interest has been the dominant positioning story over the past month. Bears added aggressively through late April, with short interest as a percentage of free float climbing from roughly 14% in early April to a peak near 17.6%, before easing slightly to 16.1% by May 5. That is a meaningful absolute level for a micro-cap biotech. The borrow market, however, shows the pressure is coming off the boil. Availability has been loosening — utilization of the lending pool pulled back from its 52-week high of 77.6% reached on April 30, down to 62.5% by May 5, indicating more room in the borrow pool than a week ago. Cost to borrow has nudged higher on the week, up 17% to 1.29%, but that remains low in absolute terms. Overall, the lending setup is firm but not extreme. Availability is still in a range that leaves room for further short building if the post-earnings reaction is negative.
Options positioning offers the sharpest single data point. The put/call ratio of 0.022 is almost at its 52-week low of 0.0223 — and sits more than 1.25 standard deviations below its 20-day average. Call-side demand is heavily dominant. That is the options market making a straightforward expression of bullish conviction ahead of the print. The contrast with a short interest ratio near 16% of float is notable: one cohort is buying calls, another has a sizable short position. The two camps appear to have been positioned for very different outcomes heading into tonight's results.
The analyst picture is largely stale — the most recent rating change is from Chardan Capital's maintain at a $8 target in mid-March, now 55 days ago. All active coverage carries Buy ratings. Price targets range from $3 to $8, with a mean around $9. Against today's close of $0.75, every analyst on the stock is structurally miles above market. That gap reflects deep scepticism baked into the share price rather than analyst error — the bears in the options data and short book have been pricing in a very different outcome than the Street's $9 mean target. Note: the large gap between the current price and analyst targets is characteristic of distressed small-cap biotech situations and does not itself imply imminent re-rating.
The institutional register adds another layer of complexity. The Column Group remains the dominant holder at 22.7% of shares, but filed sales totalling roughly 3.9 million shares across late February at prices around $0.58–$0.62. That cluster of selling by the top insider-affiliated holder came as the stock was near current levels. Vanguard and BlackRock both added meaningfully in Q1, however — Vanguard added 3.5 million shares and BlackRock added 1.6 million through March 31, providing some institutional offset to the Column Group distributions.
Past earnings reactions offer a cautionary guide. The last three reporting events saw the stock fall 8%, flat, and under 1% on the day, before drifting lower over the following week in each case — losing between 1.6% and 11.8% over the five sessions post-print. The one exception was a November 2025 event where the stock jumped 10.9% on the day before giving it all back within the week. With Q1 revenue already well above expectations and EPS slightly light, the setup heading into the after-hours reaction is one of genuine ambiguity. The call-heavy options tilt and the heavy short position will make the opening gap on Thursday the key thing to watch.
See the live data behind this article on ORTEX.
Open TNYA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
